Physician profile
Tabitha M Pollard
NPI 1891194981
$7,043.20
in general payments reported to CMS, 2019-2025
19 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,059 · 2023: $1,325 · 2024: $1,176 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.48 |
| Education | $210.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $2,041.95 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,270.60 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $683.67 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $521.70 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $513.97 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $398.33 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $387.76 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $247.75 | 2022-2025 | Trintellix |
| Abbvie INC. | $190.50 | 2022-2025 | |
| Axsome Therapeutics, INC. | $172.48 | 2024-2025 | Auvelity |
| Corium, LLC | $143.86 | 2023-2025 | Azstarys |
| Harmony Biosciences LLC | $132.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $80.05 | 2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.20 | 2023 | Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $44.87 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $38.28 | 2023 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $37.70 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $36.35 | 2023 | Spravato |
| Sage Therapeutics, LLC | $25.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.